Neuromap® AI-Based Functional & Psychological Brain Report Developed by Dr. Alptekin Aydin

October 07, 2024 10:54 PM AEDT | By EIN Presswire
 Neuromap® AI-Based Functional & Psychological Brain Report Developed by Dr. Alptekin Aydin
Image source: EIN Presswire
LONDON, ENFIELD, UNITED KINGDOM, October 7, 2024 /EINPresswire.com/ -- Cosmos Healthcare Launches Neuromap®: A Groundbreaking AI-Based Holistic Functional & Psychological Brain Report for Personalized Healthcare

Harnessing the power of AI to revolutionize brain function analysis and personalized treatment planning.

London, Cosmos Healthcare, a leader in innovative healthcare solutions, is proud to announce the launch of Neuromap®, a revolutionary AI-based system designed to generate holistic reports from quantitative EEG (qEEG) data. Neuromap® offers personalized treatment recommendations tailored to individual brain function and overall health, paving the way for more accurate diagnoses and customized healthcare strategies.

Developed by Cosmos Healthcare’s expert team led by Dr. Alptekin Aydin, Neuromap® integrates advanced artificial intelligence (AI) technology with patient qEEG scans and other critical health information. The system’s cutting-edge algorithms identify patterns and correlations that were previously undetectable through conventional methods, producing comprehensive reports that are highly personalized to the individual.

“The integration of AI into healthcare is transforming the landscape of personalized treatment,” said Dr. Alptekin Aydin, lead developer and Chief executive Officer at Cosmos Healthcare. “Neuromap® harnesses the power of AI to provide an in-depth understanding of brain activity, making it possible to offer treatment recommendations that are truly tailored to each patient’s unique neurological profile.”

Key Features of Neuromap®
Neuromap® incorporates a wide range of features to provide a holistic overview of a patient’s brain function and health needs. These reports are designed not only for medical professionals but also for patients and their families to understand and engage with the treatment process.

AI-Based Diagnosis and Recommendations: Neuromap® utilizes AI to detect paroxysmal activity in EEG data, which is crucial for diagnosing conditions like epilepsy. Based on these findings, the system generates qEEG-guided rehabilitation and treatment plans for various neurological conditions.

Personalized Recommendations: The reports include custom-tailored suggestions for therapy, education, sports, and nutrition plans, each based on the individual’s unique brain function analysis. This level of personalization ensures that treatments are more effective and responsive to the patient’s specific needs.

Family Support and Home Adjustments: Neuromap® emphasizes the importance of family involvement in the treatment process. The reports provide strategies for improving communication and support within the family unit, as well as recommendations for modifying the home environment to enhance rehabilitation outcomes.

Sports, Nutrition, and Lifestyle Plans: The holistic approach includes detailed nutrition advice—suggesting foods to eat, foods to avoid, and vitamin recommendations—alongside sports and physical activity plans tailored to the patient’s cognitive and neurological profile. This aspect of Neuromap® ensures that patients’ physical health supports their mental and neurological rehabilitation.

Educational and Professional Guidance: Neuromap® offers guidance on educational pathways and career development, with a focus on the patient’s cognitive abilities and learning needs. For individuals with autism spectrum disorder (ASD) and other conditions, Neuromap® provides specific recommendations based on international treatment programs such as Applied Behavior Analysis (ABA) and Cognitive Behavioral Therapy (CBT).

Age-Related Considerations: For older populations, Neuromap® even measures occipital alpha activity scores, which help identify risks of conditions such as Alzheimer’s and dementia. This feature is particularly beneficial for adults over 30 who may be at increased risk of age-related cognitive decline.

Revolutionizing Personalized Treatment
Neuromap® stands at the forefront of personalized healthcare, leveraging artificial intelligence to provide detailed, actionable insights into brain function and health. This AI-driven solution enables healthcare providers to offer more precise and effective treatments for patients with a wide range of neurological conditions, from epilepsy and autism to Alzheimer’s and dementia.

With Neuromap®, Cosmos Healthcare continues to push the boundaries of what is possible in modern medicine. The system’s ability to synthesize complex neurological data into a clear and actionable format empowers both healthcare providers and patients, ensuring that treatment plans are more targeted, effective, and holistic.

About Cosmos Healthcare
Cosmos Healthcare is an industry leader in AI-powered healthcare innovations, dedicated to improving patient outcomes through advanced technology and personalized care solutions. Under the guidance of Dr. Alptekin Aydin, the team at Cosmos Healthcare is committed to integrating cutting-edge research and clinical expertise into real-world healthcare applications.

Damien Hayward
Editor Special News
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
TikTok
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.